A detailed history of Gladstone Institutional Advisory LLC transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Gladstone Institutional Advisory LLC holds 15,000 shares of CRDF stock, worth $58,800. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,000
Previous 15,000 -0.0%
Holding current value
$58,800
Previous $33,000 21.21%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$1.38 - $2.18 $1,380 - $2,180
1,000 Added 7.14%
15,000 $20,000
Q3 2022

Oct 20, 2022

BUY
$1.54 - $3.21 $21,560 - $44,940
14,000 New
14,000 $22,000

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $170M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Gladstone Institutional Advisory LLC Portfolio

Follow Gladstone Institutional Advisory LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gladstone Institutional Advisory LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gladstone Institutional Advisory LLC with notifications on news.